Synfini, Inc., a trailblazer in AI-driven chemistry automation, today announced a $8.9m expansion of its round, led by JSL Health Capital and supported by a strong syndicate of early-stage investors. This brings Synfini’s total funding to $53m, comprised of non-dilutive grants and venture investment.
The company’s AI Cloud Foundry platform uniquely integrates artificial intelligence, automated synthesis, and iterative molecular design to dramatically accelerate small molecule drug discovery and synthesis. By combining physical and virtual chemistry in a unified workflow, Synfini delivers novel pharmaceutically optimized compounds at unprecedented speed, while dramatically reducing costs.
Synfini’s platform eliminates traditional bottlenecks in early drug discovery by streamlining target selection, compound design, and synthesis into an agile, integrated workflow, replacing traditional manual chemistry processes. Since its spinout from SRI in 2023, the company has validated its approach through early commercial traction and strategic partnerships.
This additional funding provides the resources necessary for further development, to scale operations, and to expand customer collaborations.
“We’re building the next generation of drug discovery infrastructure,” said Doug Donzelli, CEO of Synfini.
“This funding enables us to move faster, go broader with our platform, and deepen our relationships with both biotech innovators and large pharma. We’re grateful to be supported by a syndicate of investors who share our vision, including those who’ve backed us since the very beginning.”
The round was led by JSL Health, who joins top venture firms and deep science investors including SRI Ventures, WERU Investments, Ferocity Capital, High Water Venture Partners, Foothill Ventures, Trust Ventures, Gaingels, and Mana Ventures.
The new funding will support further hiring in scientific and engineering roles, expansion of Synfini’s software and automated lab capabilities, and growth of commercial partnerships in areas including GPCR-targeted therapeutics and precision oncology.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
